These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [What's new in multiple sclerosis therapy?]. Vaney C; Derfuss T Rev Med Suisse; 2013 Jan; 9(371):285-7. PubMed ID: 23451607 [No Abstract] [Full Text] [Related]
5. Immunologic therapy of multiple sclerosis. Arnason BG Annu Rev Med; 1999; 50():291-302. PubMed ID: 10073279 [TBL] [Abstract][Full Text] [Related]
6. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker P Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542 [TBL] [Abstract][Full Text] [Related]
8. The challenge of managing patients with multiple sclerosis. MacLean R Nurs Times; 2004 Jan 27-Feb 2; 100(4):42-4. PubMed ID: 14974264 [TBL] [Abstract][Full Text] [Related]
9. [Diagnostics and drug therapy of multiple sclerosis]. Suomen Neurologinen Yhdistys ry Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889 [No Abstract] [Full Text] [Related]
14. Approaches to neuroprotective strategies in multiple sclerosis. Tselis A; Khan OA; Lisak RP Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779 [TBL] [Abstract][Full Text] [Related]
15. Disease modification in multiple sclerosis. Sheerani M J Pak Med Assoc; 2003 Dec; 53(12):612-5. PubMed ID: 14765944 [No Abstract] [Full Text] [Related]
16. Combination therapy for multiple sclerosis: the treatment strategy of the future? Weinstock-Guttman B; Bakshi R CNS Drugs; 2004; 18(12):777-92. PubMed ID: 15377168 [TBL] [Abstract][Full Text] [Related]
17. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]. Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317 [No Abstract] [Full Text] [Related]
18. Secondary progressive multiple sclerosis: current knowledge and future challenges. Rovaris M; Confavreux C; Furlan R; Kappos L; Comi G; Filippi M Lancet Neurol; 2006 Apr; 5(4):343-54. PubMed ID: 16545751 [TBL] [Abstract][Full Text] [Related]
19. Not every patient with multiple sclerosis should be treated at time of diagnosis. Pittock SJ; Weinshenker BG; Noseworthy JH; Lucchinetti CF; Keegan M; Wingerchuk DM; Carter J; Shuster E; Rodriguez M Arch Neurol; 2006 Apr; 63(4):611-4. PubMed ID: 16606780 [No Abstract] [Full Text] [Related]
20. Update on MS treatment. Ryan M J Am Pharm Assoc (Wash); 1996 Jul; NS36(7):419-20. PubMed ID: 8840740 [No Abstract] [Full Text] [Related] [Next] [New Search]